Use of trental as an agent for preventing thrombus formation in patients with polycythemia vera
Sedova, G.T.; Krasiukova, L.I.; Kovaleva, L.G.; Malykhina, L.S.; Ermil'chenko, G.V.
Gematologiia i Transfuziologiia 29(8): 19-22
1984
ISSN/ISBN: 0234-5730 PMID: 6479557 Document Number: 226792
The treatment of patients with polycythemia vera with trental for 30 days in order to prevent thrombogenesis resulted in an elevation of blood fibrinolytic activity which was due to an increase of plasminogen and plasmin activator activity, and in significant inhibition of platelet aggregation due to the cAMP mobilization. The therapeutic effect of trental was positive. The drug is recommended for prevention of thrombogenesis in polycythemia vera.